RxDoctor Payments Data

Edgardo Gonzalez, MD

Internal Medicine · Buena Park, CANPI 1366514655

Payments from drug & device makers

$15,817in general payments, 2019–2025

Across 882 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$2K
  • GSK$1K
  • AbbVie$1K
  • Novo Nordisk$1K
  • plus $7K from 44 others

What the payments were for

  • Food & beverage$15,64799%
  • Education$1701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,817 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$63,651
Medicare patients
96
Services billed
978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol57$67,266
JardianceEmpagliflozin49$61,241
EliquisApixaban29$38,872
JanuviaSitagliptin Phosphate27$36,605
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$35,490
MounjaroTirzepatide22$27,658
ProliaDenosumab16$26,676
EntrestoSacubitril/Valsartan13$19,781
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$5,206
Losartan Potassium353$3,657
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$3,398
Atorvastatin Calcium367$3,075
Albuterol Sulfate HfaAlbuterol Sulfate107$3,049
Tamsulosin Hcl163$2,607
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,765$67,26657 claims
Boehringer IngelheimJardiance$1,677$61,24149 claims
PfizerEliquis$430$38,87229 claims
MerckJanuvia$800$36,60527 claims
GSKTrelegy Ellipta$1,289$35,49038 claims
Lilly USA, LLCMounjaro$1,880$27,65822 claims
AmgenProlia$869$26,67616 claims
NovartisEntresto$204$19,78113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Buena Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →